Literature DB >> 30992805

SGLT2 inhibitors and cirrhosis: A unique perspective on the comanagement of diabetes mellitus and ascites.

Saad Saffo1, Tamar Taddei2.   

Abstract

Entities:  

Year:  2018        PMID： 30992805      PMCID： PMC6385962          DOI： 10.1002/cld.714

Source DB:  PubMed          Journal:  Clin Liver Dis (Hoboken)        ISSN： 2046-2484


× No keyword cloud information.
  9 in total

Review 1.  Hepatogenous Diabetes: A Primer.

Authors:  Preetam Nath; Anil C Anand
Journal:  J Clin Exp Hepatol       Date:  2021-05-01

Review 2.  An Approach to the Management of Diabetes Mellitus in Cirrhosis: A Primer for the Hepatologist.

Authors:  Pankaj Puri; Narendra Kotwal
Journal:  J Clin Exp Hepatol       Date:  2021-09-16

Review 3.  Post-transplant diabetes mellitus and preexisting liver disease - a bidirectional relationship affecting treatment and management.

Authors:  Maja Cigrovski Berkovic; Lucija Virovic-Jukic; Ines Bilic-Curcic; Anna Mrzljak
Journal:  World J Gastroenterol       Date:  2020-06-07       Impact factor: 5.742

Review 4.  Lymphatic dysfunction in advanced cirrhosis: Contextual perspective and clinical implications.

Authors:  Ramesh Kumar; Utpal Anand; Rajeev Nayan Priyadarshi
Journal:  World J Hepatol       Date:  2021-03-27

Review 5.  Selection and Warning of Evidence-Based Antidiabetic Medications for Patients With Chronic Liver Disease.

Authors:  Fu-Shun Yen; Chih-Cheng Hsu; James Cheng-Chung Wei; Ming-Chih Hou; Chii-Min Hwu
Journal:  Front Med (Lausanne)       Date:  2022-02-16

Review 6.  Clinical implications of diabetes in chronic liver disease: Diagnosis, outcomes and management, current and future perspectives.

Authors:  Diego García-Compeán; Emanuela Orsi; Ramesh Kumar; Felix Gundling; Tsutomu Nishida; Jesús Zacarías Villarreal-Pérez; Ángel N Del Cueto-Aguilera; José A González-González; Giuseppe Pugliese
Journal:  World J Gastroenterol       Date:  2022-02-28       Impact factor: 5.742

Review 7.  SGLT2 Inhibitors as the Most Promising Influencers on the Outcome of Non-Alcoholic Fatty Liver Disease.

Authors:  Luigi Mirarchi; Simona Amodeo; Roberto Citarrella; Anna Licata; Maurizio Soresi; Lydia Giannitrapani
Journal:  Int J Mol Sci       Date:  2022-03-27       Impact factor: 5.923

8.  Risk of infections in patients with NAFLD and Type 2 Diabetes under treatment with SGLT2 inhibitors and relationship with liver outcomes: A retrospective case-control study.

Authors:  Juan Bañares; Ramiro Manzano-Nuñez; Alba Prió; Jesús Rivera-Esteban; Laura Camps-Relats; Ana Villarejo; Lourdes Ruiz-Ortega; Mònica Pons; Andreea Ciudin; María Teresa Salcedo; Víctor Vargas; Joan Genescà; Juan M Pericàs
Journal:  Front Endocrinol (Lausanne)       Date:  2022-08-24       Impact factor: 6.055

9.  Impact of SGLT2 inhibitors in comparison with DPP4 inhibitors on ascites and death in veterans with cirrhosis on metformin.

Authors:  Saad Saffo; David E Kaplan; Nadim Mahmud; Marina Serper; Binu V John; Joseph S Ross; Tamar Taddei
Journal:  Diabetes Obes Metab       Date:  2021-07-28       Impact factor: 6.408
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.